Left atrial appendage closure with the AnchorMan or Watchman devices: 12-month results of the SAFE-PROTECT randomised trial
EuroIntervention · 2026
DOI: 10.4244/eij-d-25-01168 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift EuroIntervention, 2026. Verfasst von Binhao Wang und 17 weiteren Autor:innen. Beteiligte Einrichtung: Arrhythmia Center, First Affiliated Hospital of Ningbo University, Ningbo, China. Hauptthemen laut MEDLINE: Left Atrial Appendage Closure, Atrial Fibrillation, Stroke, Atrial Appendage. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND: Percutaneous closure of the left atrial appendage (LAA) is an alternative to chronic oral anticoagulation to reduce stroke risk in patients with non-valvular atrial fibrillation (AF). AIMS: The SAFE-PROTECT trial was designed to evaluate the safety and efficacy of the AnchorMan, a novel LAA closure device, compared with the Watchman 2.5 device for patients with AF at high risk of ischaemic stroke. METHODS: SAFE-PROTECT was a multicentre, open-label, non-inferiority trial of patients with non-valvular AF at high risk of ischaemic stroke, randomised 1:1 to LAA closure with the AnchorMan or the Watchman device. The 12-month primary endpoint was clinical success (freedom from ischaemic/haemorrhagic stroke, systemic embolism, cardiovascular or unexplained death); the secondary efficacy endpoint was echocardiography-defined LAA occlusion (peridevice leak 0.99; difference -0.3; 95% confidence interval [CI]: -3.9 to 3.5; pnon-inferiority=0.0004) and the powered secondary efficacy endpoint of LAA closure (100% vs 100%; difference 0%; 95% CI: -3.60 to 3.50; pnon-inferiority=not applicable). The rates of all-cause death, stroke, major bleeding, and device-related complications were low and similar between groups. CONCLUSIONS: Among patients with non-valvular AF at high risk of ischaemic stroke, the AnchorMan device met its prespecified non-inferiority primary clinical success and secondary LAA occlusion endpoints compared with the Watchman 2.5 device. CLINICALTRIALS: gov: NCT04479722.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Arrhythmia Center, First Affiliated Hospital of Ningbo University, Ningbo, China.
- Department of Cardiology, Tianjin Medical University General Hospital, Tianjin, China.
- Department of Cardiology, Second Affiliated Hospital of Nanchang, Nanchang, China.
- Department of Cardiology, Central Hospital of Wuhan, Wuhan, China.
- Department of Cardiology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Cardiology, Zhuhai People's Hospital, Zhuhai, China.
Zitieren
APA
Wang, B., Cai, H., Wu, Y., Chen, M., Wang, C., Jiang, X., Tao, S., Zhong, Z., Zeng, J., Wang, F., Ning, Z., Yuan, Z., He, J., Francese, D. P., Lansky, A. J., He, B., Chu, H., & Of The Safe-Protect Investigators, O. B. (2026). Left atrial appendage closure with the AnchorMan or Watchman devices: 12-month results of the SAFE-PROTECT randomised trial. EuroIntervention. https://doi.org/10.4244/eij-d-25-01168
Vancouver
Wang B, Cai H, Wu Y, Chen M, Wang C, Jiang X, et al. Left atrial appendage closure with the AnchorMan or Watchman devices: 12-month results of the SAFE-PROTECT randomised trial. EuroIntervention. 2026. doi:10.4244/eij-d-25-01168
BibTeX
@article{Wang2026,
author = {Wang, Binhao and Cai, Heng and Wu, Yanqing and Chen, Manhua and Wang, Changqian and Jiang, Xiaofei and Tao, Siming and Zhong, Zhixiong and Zeng, Jie and Wang, Fengling and Ning, Zhongping and Yuan, Zuyi and He, Jiangui and Francese, Dominic P and Lansky, Alexandra J and He, Ben and Chu, Huimin and Of The Safe-Protect Investigators, On Behalf},
title = {Left atrial appendage closure with the AnchorMan or Watchman devices: 12-month results of the SAFE-PROTECT randomised trial},
journal = {EuroIntervention},
year = {2026},
doi = {10.4244/eij-d-25-01168}
}
EUVIMED